Daratumumab, Lenalidomide, and Dexamethasone (DRD), an Active Regimen in the Treatment of Immunosuppression-Associated Plasmablastic Lymphoma (PBL) in the Setting of Gorham’s Lymphangiomatosis: Review of the Literature

<div>Pathology slides. (a) H&amp;E stain of core biopsy. (b) High Kappa expression. (c) Negative lambda expression. (d) Positive cMYC expression. (e) Positive MUM-1 expression. (f) High Ki-67 expression. (g) Negative CD20 expression. (h) Negative EBER ISH.</div>

Case Reports in Hematology

fig1

Figure 1

Figure 1: Daratumumab, Lenalidomide, and Dexamethasone (DRD), an Active Regimen in the Treatment of Immunosuppression-Associated Plasmablastic Lymphoma (PBL) in the Setting of Gorham’s Lymphangiomatosis: Review of the Literature 

Figure 1 | Daratumumab, Lenalidomide, and Dexamethasone (DRD), an Active Regimen in the Treatment of Immunosuppression-Associated Plasmablastic Lymphoma (PBL) in the Setting of Gorham’s Lymphangiomatosis: Review of the Literature 